Last update 08 May 2025

CDH17 x CEACAM5 x CD3

Basic Info

Related Targets
CDH17CEACAM5CD3

Related

1
Drugs associated with CDH17 x CEACAM5 x CD3
CEACAM5/CDH17/CD3 Trispecific TCE(Helixon)
Target
CD3 x CDH17 x CEACAM5
Mechanism
CD3 stimulants [+2]
Active Org.
Helixon US, Inc.
Originator Org.
Helixon US, Inc.
Active Indication
Colorectal Cancer
Inactive Indication-
Drug Highest PhasePreclinical
First Approval Ctry. / Loc.-
First Approval Date20 Jan 1800
100 Clinical Results associated with CDH17 x CEACAM5 x CD3
Login to view more data
100 Translational Medicine associated with CDH17 x CEACAM5 x CD3
Login to view more data
0 Patents (Medical) associated with CDH17 x CEACAM5 x CD3
Login to view more data

Analysis

Perform a panoramic analysis of this field.
login
or
view full example data
Perform a panoramic analysis of this field.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free